BMY 45778

Key Product Details

Product Description

BMY 45778 is a non-prostanoid prostacyclin mimetic that acts as a partial agonist at IP₁ prostacyclin receptors. Potently inhibits platelet aggregation in vitro (IC₅₀ = 27-35 nM).

Licensing Information

Sold with the permission of Bristol-Myers Squibb Company

Product Specifications for BMY 45778

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for BMY 45778

The following data is based on the product molecular weight 438.44.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.5 mM	4.56 mL	22.81 mL	45.62 mL
2.5 mM	0.91 mL	4.56 mL	9.12 mL
5 mM	0.46 mL	2.28 mL	4.56 mL
25 mM	0.09 mL	0.46 mL	0.91 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Seiler [3-[4-(4,5-Diphenyl-2-oxazolyl)-5-oxazolyl]phenoxy]acetic acid (BMY 45778) is a potent non-prostanoid prostacyclin partial agonist: effects on platelet aggregation, adenylyl cyclase, cAMP levels, protein kinase, and ilo. binding. Prostaglandins 1997 PMID: 9068064
• Rudd Non-prostanoid prostacyclin mimetics as neuronal stimulants in the rat: comparison of vagus nerve and NANC innervation of the colon. Br.J.Pharmacol. 2000 PMID: 10683203

Product Documents for BMY 45778